Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

metastatic Metastatic Squamous Neck Cancer With Occult Primary

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Metastatic squamous neck cancer with occult primary can recur (come back) after it has been treated.

Broader topic: Metastatic Squamous Neck Cancer With Occult Primary

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
      source wording
      Metastatic squamous neck cancer with occult primary can recur (come back) after it has been treated.

      Study evidence for this setting

      9 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00095628 · Registry condition search · Scope: unclear

      SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00387335 · Registry condition search · Scope: unclear

      Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

      4 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT00507767 · Registry condition search · Scope: unclear

      Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00513435 · Registry condition search · Scope: unclear

      Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      2 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00939627 · Registry condition search · Scope: unclear

      Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

      6 outcome links · 2 safety-group records · 1 quality-of-life measures

      →

      NCT01044433 · Registry condition search · Scope: unclear

      Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01806675 · Registry condition search · Scope: unclear

      18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

      5 outcome links · 3 safety-group records · 1 quality-of-life measures

      →

      NCT01816984 · Registry condition search · Scope: unclear

      PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02644122 · Registry condition search · Scope: unclear

      SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

      5 outcome links · 1 safety-group records · 1 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice